Finger-prick blood tests which quickly detect the deadliest type of stroke could save lives
A finger-prick blood test to diagnose the deadliest form of stroke might be twice as effective at spotting it than using a patient's symptoms alone.
The test, which works similarly to a lateral flow test used to detect Covid, is being piloted by ambulance crews in Cambridgeshire.
The blood tests have been designed to detect if someone has suffered a large vessel occlusion (LVO), where a blood clot blocks a major artery in the brain.
This type of blood clot is responsible for about a third of strokes but causes about 95 per cent of disabilities and deaths.
A stroke is a very serious condition where the blood supply to part of your brain is cut off, and every minute a stroke is left untreated some 1.9 million brain cells die, increasing the risk of serious long-term disability and death, according to the Stroke Association.
But speedy treatment for a stroke can dramatically increase a patient's chances of recovery. This includes a thrombectomy procedure to remove the blood clot within a few hours of any symptoms appearing.
However, only 24 hospitals in the UK can provide thrombectomy treatment, and LVO is tricky to diagnose without a brain scan because it has similar symptoms to other conditions.
Due to a combination of NHS pressures and workforce shortages, these timeframes are often missed and only 3.9 per cent of eligible stroke patients had a thrombectomy in 2023/24 - against NHS England's target of 10 per cent by 2027/28.
In addition, only 46 per cent were admitted to a stroke unit within four hours of arriving at a hospital, which further reduces the treatment window and the patient's chances of recovery, the Stroke Association added.
As a result, unless a patient is lucky enough to live near a specialist centre, in most cases they will be taken to a general hospital. From there, it can take an average of three hours to be moved to a thrombectomy centre. However, these new finger-prick blood tests help diagnose LVOs faster and get patients the treatment they need.
The test, developed by the Cambridge-based firm UpFront Diagnostics, consists of two lateral flow cartridges and can detect two molecules in the blood.
One is a protein called D-dimer, which is associated with blood clots, and the other, called GFAP, is associated with bleeding in the brain. The absence of GFAP helps to rule out a haemorrhagic stroke where a blood vessel ruptures and bleeds, The Guardian reported.
These tests can detect LVOs with about 90 per cent accuracy within 15 minutes — which is more than double the accuracy of just checking symptoms, Gonzalo Ladreda, UpFront's chief executive officer, told the newspaper.
Dr Louise Flanagan, the head of research for the Stroke Association, which helps fund the early development of the LVOne test, told The Independent: 'When the NHS is under huge pressure and its workforce is in crisis, a simple finger prick test to help diagnose stroke could be revolutionary.
'The LVOne test could potentially diagnose stroke faster and much more affordably than the only current alternative, which is a brain scan. It could also help to identify the type of stroke a person is having, which is vital to ensure the right treatment is given.
'LVOne could help make it easier to decide whether someone is having a stroke that could be treated with a thrombectomy, saving the NHS time and money and, importantly, helping more people live well after stroke.'
The Stroke Association is calling for improvements in stroke care as part of the 10 Year Health Plan — to help meet the government's own target to reduce stroke disability and death by 25 per cent by 2035.
A Department of Health and Social Care spokesperson said: "This government is taking action to tackle the biggest killers like heart disease and strokes.
"We have introduced health checks in workplaces and blood pressure checks on high streets to help catch illness earlier, and we are acting to prevent strokes in the first place by tackling smoking and obesity.
"We are committed to improving stroke prevention, treatment, and recovery through our 10-Year Health Plan, which will emphasise prevention and make better use of innovative technology like prehospital video triage (PVT) as we shift the NHS from analogue to digital."
There are 1.3 million stroke survivors in the UK, and 100,000 people have strokes every year. But 90 per cent of these are preventable, the charity said. Lifestyle factors such as obesity, smoking, alcohol intake and exercise levels can have a significant effect on a person's stroke risk.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
32 minutes ago
- Yahoo
MemoDefend Announces Official Website Update Featuring Natural Daily Supplement for Cognitive Support
Natural Brain Health Formula Now Available Online to Support Memory, Focus, and Cognitive Function in Adults Lakeland, June 09, 2025 (GLOBE NEWSWIRE) -- MemoDefend, a Florida-based wellness brand, has updated its official website to provide consumers with new information about its daily supplement formulated to support cognitive clarity and brain function in adults. Now available nationwide, the natural memory support formula is designed for individuals seeking a consistent, easy-to-integrate wellness solution. According to the official product website ( MemoDefend is intended to work in harmony with the body's internal processes to support healthy memory retention, mental sharpness, and overall cognitive performance. The brand highlights its approach as one that simplifies brain wellness without requiring restrictive regimens or complicated routines. 'We developed MemoDefend to help adults support brain health naturally—without disrupting their lifestyle,' said a company spokesperson. 'This product reflects our focus on purity, simplicity, and long-term wellness.' The company states that MemoDefend is produced in facilities that follow strict quality control practices. Its formulation features a selection of ingredients that align with adult wellness priorities such as cognitive support, mental clarity, and healthy aging. As noted on the website, MemoDefend includes a satisfaction guarantee for new customers. Those interested in learning more about its intended use or placing an order can find full details, customer support access, and purchasing options directly at the official website. About MemoDefend MemoDefend is a Lakeland, Florida-based wellness brand committed to delivering natural, easy-to-use supplements that support everyday health routines. Focused on transparency and simplicity, the company develops formulas to help adults feel more confident in their wellness journey—one daily step at a time. Product and Contact Information Brand: MemoDefendWebsite: support@ +1 (888) 535-1590Mailing Address: P.O. Box 90129, Lakeland, FL 33804, United States Disclaimer This release is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. The statements made about this product have not been evaluated by the Food and Drug Administration. Individual results may vary. Consumers should consult a qualified healthcare provider before beginning any new dietary supplement. CONTACT: Email: support@ Phone: +1 (888) 535-1590Sign in to access your portfolio
Yahoo
40 minutes ago
- Yahoo
Women with genetic cancer risk being ‘missed' due to testing gaps
Families of some cancer patients are being denied the chance to find out about their cancer risk due to gaps in genetic testing, a new study has suggested. A lack of testing for Lynch syndrome also means some cancer patients are unaware of their risk of developing other cancers, academics said. Lynch syndrome is a rare condition which runs in families which puts people at a higher risk of developing cancers of the bowel, womb and ovaries. It is caused by a mutation in the gene that fixes mistakes in DNA when it is copied, which can lead to uncontrolled cell growth. Patients with bowel or womb cancer should have their tumours assessed for markers of Lynch syndrome, according to guidance for the NHS. If these markers are identified, patients should be referred for genetic testing so the diagnosis can be confirmed and they can get support and advice about cancer risk for themselves and their family. A new study by academics at the University of Edinburgh found not all womb cancer patients are being sent for genetic testing. Researchers examined data on 2,500 womb cancer patients across the UK and Ireland between 2022 and 2023. We have launched a Guide to #LynchSyndrome to help provide information and support to anyone who thinks they may have it, that it may run in the family, or have found out they have — The Eve Appeal (@eveappeal) February 13, 2023 They found that 91% of tumours were tested for markers of Lynch syndrome, but the test results were not routinely communicated to the wider clinical team. This means that follow-up genetic counselling and blood tests were not always arranged. Of the 181 participants eligible for genetic counselling, just under two-thirds (64%) were referred for appointments, according to the study, which has been published in the journal BMJ Oncology. Researchers said those who were referred faced long waits, resulting in high dropout rates, meaning only 48% of those eligible went on to get the test. Today's #LynchSyndromeAwarenessDay. Our policy team sat down with our supporter, Jane, to share her experience. As well as highlighting what else needs to be done to improve Lynch syndrome care. Read our blog: — Bowel Cancer UK (@bowelcanceruk) March 22, 2025 Experts from the university said gaps in testing mean some womb cancer patients with Lynch syndrome go undetected. Family members are also left vulnerable to cancer risk, unaware they may have the condition. Dr Neil Ryan, from the University of Edinburgh, who leads the UK audit and research collaborative in obstetrics and gynaecology, said: 'Despite clear guidance and excellent rates of tumour testing, too many women with Lynch syndrome are still being missed because they're not referred for definitive blood testing in a timely way. 'This not only denies them the chance to reduce their future cancer risk but also prevents their relatives from being tested and protected. 'Tumour testing is only cost-effective if it leads to diagnosis — we urgently need to make mainstream testing truly mainstream.'
Yahoo
an hour ago
- Yahoo
Diabetes scheme reduces risk of condition by quarter
A diabetes prevention programme in Wales could reduce the risk of developing the condition by nearly a quarter, research has shown. But the all-Wales programme "doesn't currently live up to its name" as it only operates in parts of Wales, a charity said. Diabetes affects more than 220,000 people in Wales with projections it could rise by 22% over the next decade. Rachel Burr, head of Diabetes UK Cymru, said NHS costs had also risen and called for money to be invested in patients before they start to live with the condition. The Welsh government said funding has been allocated this year to make further progress in embedding delivery in core activity and rolling it out across Wales. Following a pilot in two parts of Wales, in 2022 the gradual roll out began with 35 of the 60 primary care clusters in Wales, prioritising areas in each health board with a high prevalence of type 2 diabetes. Funded by the Welsh government but provided by health boards, it has now been offered to more than 10,000 people across Wales. "So many people in Wales will not have access to this programme currently and that's an inequity – its not fair," said Ms Burr. "We want everyone to have access to the same level of support and care because diabetes is such a serious condition. "It's actually at crisis levels in Wales and continuing to rise and we need to make sure we're getting people the help they need before they develop diabetes if possible." David Weekes from Swansea has been among those to benefit from the prevention programme. The 67-year-old only discovered he was pre-diabetic when he went to the GP about an unrelated rash on his knees, and was sent to see the prevention team in Penclawdd. "We talked about my diet and exercise and I went back for a follow-up appointment this year," he said. "In that time I have lost 2st 1lb (13kg). I stopped eating as many biscuits and cakes and I now go to the gym every day. "I feel a lot better in myself for doing it and my glucose levels have come right down." Ms Weekes said while he was not unfit before, it gave him the warning "I needed". "I now cycle seven days a week, for about 15-16 miles (25km), and I do weightlifting in the gym." The scheme uses a blood test, called an HbA1c test, to identify those at increased risk of developing type 2 diabetes by measuring their average blood sugar levels. Those with levels between 42-47 millimoles per mole are classed as at increased risk and offered a 30-minute appointment with a healthcare support worker, where information and support is provided. A follow up appointment then takes place a year later. Dr Sarah Davies, a GP in Cardiff and primary care lead for diabetes in Wales, said blood tests would often identify someone is borderline for type 2 diabetes, but "until now we haven't had anywhere we can refer those individuals to get that support". "Primary care is on our knees and under-resourced across Wales. So sometimes those patients haven't received much in the way of information about pre diabetes. "That's why I so welcome this program to enable us to refer these individuals into a community service. "I'm hoping now that we've got this study that clearly demonstrates the benefits, this will support more widespread funding for this innovative program here in NHS Wales." She added that patients sometimes feel shame attached to being told they are pre-diabetic. "There's a lot of blame associated with it, which is not the case. There's many reasons why people end up living with overweight, obesity and at risk of type two diabetes, many complex environmental, genetic reasons. "So sometimes people don't want to face up to it, but actually giving one to one support via this program is a lovely way to be able to give an individualized approach." Alisha Davies, head of research and evaluation at Public Health Wales, said results have shown the programme has been been effective in "stalling and reducing progression" to diabetic blood glucose levels. She said "robust monitoring and evaluation" will help to understand its impact over time on "an important preventable disease in Wales". Staff from one primary care cluster in Swansea have also taken the screening to a local mosque to identify those who are either pre-diabetic or have undiagnosed diabetes. Dr Wynn Burke said: "Our practice population includes a significant Asian community who are known to be at higher risk of diabetes from a much younger age. "We do a lot of diabetes screening in high-risk individuals as part of our normal practice. "However, the percentage of our practice population with a diagnosis of type 2 diabetes remains below the expected ratio, therefore we sought to reach out and bridge potential health inequalities." Caroline Ashwood, an advanced nurse practitioner at SA1 Medical Centre, said around a fifth of the 140 people screened over three days so far had been identified as pre-diabetic, and three had diabetes. "Swansea Mosque is based within our (cluster area), and it is one of the largest in the UK with around 10,000 members, so this was a great opportunity to bridge health inequalities," she said. "The team at Swansea Mosque were equally proactive in working together. They set up the online booking system and supported us on the screening days we have already carried out." The Welsh government said: "We know preventative support makes a real difference in reducing the risk of people with prediabetes developing type 2 diabetes, and funding from a variety of sources has been used to develop and extend the programme. "To ensure more people across Wales can benefit from early support, funding has also been allocated this year to make further progress in embedding delivery in core activity and rolling out across Wales." There are more than 220,000 people in Wales with diabetes – predominantly with type 2 which is preventable – and the numbers have steadily risen in Wales. Projections by Public Health Wales (PHW) suggest that without intervention, by 2035 there will be a 22% rise in those numbers. The figures are higher among older people and men, though Diabetes UK Cymru said they were seeing more cases of people under 40 developing the condition. PHW research shows the cost and volume of medicines prescribed for diabetes has been steadily increasing over the last decade. The cost of medicine ingredients alone has risen 56% in the last five years and is now over £90m in Wales, partly because of the increase in the numbers of items prescribed. There were also 90,000 hospital admissions attributed to diabetes in Wales during 2021/2022. Type 2 diabetes is where the body does not produce enough insulin, or the body's cells do not react to insulin properly. Healthy eating, regular exercise and a healthy body weight reduce the risk of developing it. The condition can cause excessive thirst, tiredness and the need to go for a wee a lot. It can also lead to complications like heart disease, stroke, kidney disease, retina damage and foot problems if not managed well.
